secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001628280-23-027227
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q2 net loss $194.8M; hep B/delta data on track for Q4
-----------------------------------------------------------------

- Net loss $194.8M ($1.45/sh) vs $76.5M loss YoY; revenues $3.8M (incl $16.5M grant).
- Cash $1.9B at June 30; $273.6M paid to GSK for excess sotrovimab supply.
- Discontinued innate immunity small molecule platform to focus on antibody platform.
- Phase 2 PENINSULA flu trial (VIR-2482) missed primary and secondary endpoints.
- Phase 2 hep B/delta data (VIR-2218/VIR-3434) expected Q4 2023; HIV vaccine VIR-1388 Phase 1 dosing expected Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828023027227/0001628280-23-027227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828023027227/vir-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer